Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical stage RXR agonist for treatment of normal aging-related neurodegeneration, at the FASEB Science Research Conference on Cellular and Molecular Mechanisms of Brai 18-09-2024, 22:07

Bringing confident diagnosis to more patients at low cost: Philips launches new AI-enabled CT 5300 at #ECR2024 29-02-2024, 16:00

Duck Creek Technologies Announces New Chief Marketing Officer 20-05-2024, 19:30